fenofibrate has been researched along with Infarction, Middle Cerebral Artery in 4 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Infarction, Middle Cerebral Artery: NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fenofibrate treatment has neuroprotective effects on middle cerebral artery infarcts." | 5.46 | Neuroprotective Effects of Chronic Fenofibrate Treatment via Modulating the Immunoreactivity of Cleaved Caspase-3 in Stroke Induced by Transient Middle Cerebral Artery Occlusion Rat Model. ( Altintas, MO; Altintas, O; Antar, V; Asil, T; Aydin, MS; Baran, O; Esrefoglu, M, 2017) |
| "Fenofibrate treatment has neuroprotective effects on middle cerebral artery infarcts." | 1.46 | Neuroprotective Effects of Chronic Fenofibrate Treatment via Modulating the Immunoreactivity of Cleaved Caspase-3 in Stroke Induced by Transient Middle Cerebral Artery Occlusion Rat Model. ( Altintas, MO; Altintas, O; Antar, V; Asil, T; Aydin, MS; Baran, O; Esrefoglu, M, 2017) |
| "We conclude that PPARα agonist treatment prior to stroke is neuroprotective in males but not females." | 1.43 | Sex differences and the role of PPAR alpha in experimental stroke. ( Chen, Y; Dotson, AL; Manning, D; Nguyen, H; Offner, H; Saugstad, JA; Wang, J, 2016) |
| "A 1-h intraluminal thread middle cerebral artery occlusion (MCAO) model followed by a 6-h reperfusion was performed in C57/BL6 mice." | 1.42 | The role of PPAR activation during the systemic response to brain injury. ( Anthony, DC; Bordet, R; Burns, L; Guevel, B; Ladds, E; Laprais, M; Losey, P, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Losey, P | 1 |
| Ladds, E | 1 |
| Laprais, M | 1 |
| Guevel, B | 1 |
| Burns, L | 1 |
| Bordet, R | 2 |
| Anthony, DC | 1 |
| Dotson, AL | 1 |
| Wang, J | 1 |
| Chen, Y | 1 |
| Manning, D | 1 |
| Nguyen, H | 1 |
| Saugstad, JA | 1 |
| Offner, H | 1 |
| Altintas, O | 1 |
| Altintas, MO | 1 |
| Aydin, MS | 1 |
| Baran, O | 1 |
| Antar, V | 1 |
| Esrefoglu, M | 1 |
| Asil, T | 1 |
| Deplanque, D | 1 |
| Gelé, P | 1 |
| Pétrault, O | 1 |
| Six, I | 1 |
| Furman, C | 1 |
| Bouly, M | 1 |
| Nion, S | 1 |
| Dupuis, B | 1 |
| Leys, D | 1 |
| Fruchart, JC | 1 |
| Cecchelli, R | 1 |
| Staels, B | 1 |
| Duriez, P | 1 |
4 other studies available for fenofibrate and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
The role of PPAR activation during the systemic response to brain injury.
Topics: Analysis of Variance; Animals; Brain Injuries; Chemokine CXCL1; Chemokine CXCL10; Disease Models, An | 2015 |
Sex differences and the role of PPAR alpha in experimental stroke.
Topics: Animals; Brain; Female; Fenofibrate; Hypolipidemic Agents; Infarction, Middle Cerebral Artery; Male; | 2016 |
Neuroprotective Effects of Chronic Fenofibrate Treatment via Modulating the Immunoreactivity of Cleaved Caspase-3 in Stroke Induced by Transient Middle Cerebral Artery Occlusion Rat Model.
Topics: Animals; Brain; Caspase 3; Caspase Inhibitors; Disease Models, Animal; Fenofibrate; Infarction, Midd | 2017 |
Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment.
Topics: Animals; Apolipoproteins E; Cerebral Infarction; Cerebrovascular Circulation; Disease Models, Animal | 2003 |